• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

FDA Approves First Self-Administered Flu Vaccine: Daily Dose

News
Article
FDA Approves First Self-Administered Flu Vaccine: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On September 20, 2024, we reported on the US Food and Drug Administration (FDA) approval of FluMist (influenza vaccine live, intranasal; AstraZeneca), for self- or caregiver-administration.

The approval

FluMist is the first influenza vaccine that does not require administration by a health care professional. FluMist is already approved for the prevention of influenza caused by subtypes A and B in individuals aged 2 to 49 years. Individuals can still receive the vaccine from a health care professional in a health care setting, including the pharmacy, or administer it themselves or via a caregiver aged 18 years and older. Those who choose self- or caregiver administration will receive the vaccine from a third-party online pharmacy, along with instructions for use and storage, administration, and disposal.

The FDA's decision comes after a supplemental biologic license application (sBLA) was submitted by AstraZeneca in October 2023. The sBLA was supported by a usability study confirming the vaccine's feasibility.

Click here for more details.


Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
© 2024 MJH Life Sciences

All rights reserved.